Clinical Trials
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Open
Accrual
0%
SWOG Clinical Trial Number
S1706
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Status Notes
Activation, Effective 9/12/2018, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
ClinicalTrials.gov Registry Number
NCT03598257
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1701
A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status Notes
This study is open to accrual effective 8/9/18.
Research Committee(s)
Lung Cancer
Activated
08-09-2018
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1712
A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Status Notes
The study is open to accrual effective 7/20/18.
Research Committee(s)
Leukemia
Activated
07-20-2018
Open
Accrual
0%
SWOG Clinical Trial Number
S1703
Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
Status Notes
The above-referenced study is open for participation effective July 16, 2018 at 2:00
p.m. Eastern Time.
p.m. Eastern Time.
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Activated
07-16-2018
Open
Accrual
28%
SWOG Clinical Trial Number
S1702
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Status Notes
This study is active for patient participation effective 3/8/18 at 2:00 p.m. Eastern.
Research Committee(s)
Myeloma
Activated
03-08-2018